PDZRN3/LNX3 is a novel target of human papillomavirus type 16 (HPV-16) and HPV-18 E6

Journal of Virology

Volumn 89, Issue 2, 2015, Pages 1439-1444

  Thomas, Miranda ^a   Banks, Lawrence ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE TRANSFERASE; PDZ PROTEIN; PROTEIN E6; RING FINGER PROTEIN; RING FINGER PROTEIN CONTAINING UBIQUITIN PROTEIN LIGASE PDZRN3; STAT5B PROTEIN; UNCLASSIFIED DRUG; CARRIER PROTEIN; DNA BINDING PROTEIN; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18; ONCOPROTEIN; PDZRN3 PROTEIN, HUMAN; PROTEASOME; REPRESSOR PROTEIN;

ARTICLE; BINDING AFFINITY; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CARCINOGENICITY; CELL DIFFERENTIATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA TUMOR VIRUS; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; NONHUMAN; PDZ DOMAIN; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; VIROGENESIS; VIRUS CELL INTERACTION; FEMALE; HOST PATHOGEN INTERACTION; METABOLISM; PHYSIOLOGY;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

CARRIER PROTEINS; DNA-BINDING PROTEINS; FEMALE; HOST-PATHOGEN INTERACTIONS; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; ONCOGENE PROTEINS, VIRAL; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; REPRESSOR PROTEINS;

EID: 84920842365     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01743-14     Document Type: Article

References (26)

1. IARC Working Group on the Evaluation of Carcinogenic Risk to Humans. 2012. Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum 100(Pt B):1-441.
2. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V, WHO International Agency for Research on Cancer Monograph Working Group. 2009. A review of human carcinogens-part B: biological agents. Lancet Oncol 10:321-322. http://dx.doi.org/10.1016/S1470-2045(09)70096-8.
3. Pim D, Bergant M, Boon SS, Ganti K, Kranjec C, Massimi P, Subbaiah VK, Thomas M, Tomaić V, Banks L. 2012. Human papillomaviruses and the specificity of PDZ domain targeting. FEBS J 279:3530-3537. http://dx.doi.org/10.1111/j.1742-4658.2012.08709.x.
4. Nguyen ML, Nguyen MM, Lee D, Griep AE, Lambert PF. 2003. The PDZ ligand domain of the human papillomavirus type 16 E6 protein is required for E6's induction of epithelial hyperplasia in vivo. J Virol 77: 6957-6964. http://dx.doi.org/10.1128/JVI.77.12.6957-6964.2003.
5. Lee C, Laimins LA. 2004. Role of the PDZ domain-binding motif of the oncoprotein E6 in the pathogenesis of human papillomavirus type 31. J Virol 78:12366-12377. http://dx.doi.org/10.1128/JVI.78.22.12366-12377.2004.
6. Nicolaides L, Davy C, Raj K, Kranjec C, Banks L, Doorbar J. 2011. Stabilization of HPV16 E6 protein by PDZ proteins, and potential implications for genome maintenance. Virology 414:137-145. http://dx.doi.org/10.1016/j.virol.2011.03.017.
7. Delury CP, Marsh EK, James CD, Boon SS, Banks L, Knight GL, Roberts S. 2013. The role of protein kinase A regulation of the E6 PDZbinding domain during the differentiation-dependent life cycle of human papillomavirus type 18. J Virol 87:9463-9472. http://dx.doi.org/10.1128/JVI.01234-13.
8. Brimer N, Vande Pol SB. 2014. Papillomavirus E6 PDZ interactions can be replaced by repression of p53 to promote episomal human papillomavirus genome maintenance. J Virol 88:3027-3030. http://dx.doi.org/10.1128/JVI.02360-13.
9. Gardiol D, Kühne C, Glaunsinger B, Lee SS, Javier R, Banks L. 1999. Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation. Oncogene 18: 5487-5496. http://dx.doi.org/10.1038/sj.onc.1202920.
10. Nakagawa S, Huibregtse JM. 2000. Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase. Mol Cell Biol 20:8244-8253. http://dx.doi.org/10.1128/MCB.20.21.8244-8253.2000.
11. Glaunsinger BA, Lee SS, Thomas M, Banks L, Javier R. 2000. Interactions of the PDZ-protein MAGI-1 with adenovirus E4-ORF1 and highrisk papillomavirus E6 oncoproteins. Oncogene 19:5270-5280. http://dx.doi.org/10.1038/sj.onc.1203906.
12. Kranjec C, Banks L. 2011. A systematic analysis of human papillomavirus (HPV) E6 PDZ substrates identifies MAGI-1 as a major target ofHPVtype 16 (HPV-16) and HPV-18 whose loss accompanies disruption of tight junctions. J Virol 85:1757-1764. http://dx.doi.org/10.1128/JVI.01756-10.
13. Rozenblatt-Rosen O, Deo RC, Padi M, Adelmant G, Calderwood MA, Rolland T, Grace M, Dricot A, Askenazi M, Tavares M, Pevzner SJ, Abderazzaq F, Byrdsong D, Carvunis AR, Chen AA, Cheng J, Correll M, Duarte M, Fan C, Feltkamp MC, Ficarro SB, Franchi R, Garg BK, Gulbahce N, Hao T, Holthaus AM, James R, Korkhin A, Litovchick L, Mar JC, Pak TR, Rabello S, Rubio R, Shen Y, Singh S, Spangle JM, Tasan M, Wanamaker S, Webber JT, Roecklein-Canfield J, Johannsen E, Barabási AL, Beroukhim R, Kieff E, Cusick ME, Hill DE, Münger K, Marto JA, Quackenbush J, Roth FP, DeCaprio JA, Vidal M. 2012. Interpreting cancer genomes using systematic host network perturbations by tumour virus proteins. Nature 487:491-495. http://dx.doi.org/10.1038/nature11288.
14. Belotti E, Polanowska J, Daulat AM, Audebert S, Thomé V, Lissitzky JC, Lembo F, Blibek K, Omi S, Lenfant N, Gangar A, Montcouquiol M, Santoni MJ, Sebbagh M, Aurrand-Lions M, Angers S, Kodjabachian L, Reboul J, Borg JP. 2013. The human PDZome: a gateway to PSD95-Disc large-zonula occludens (PDZ)-mediated functions. Mol Cell Proteomics 12:2587-2603. http://dx.doi.org/10.1074/mcp.O112.021022.
15. Flynn M, Saha O, Young P. 2011. Molecular evolution of the LNX family. BMC Evol Biol 11:235. http://dx.doi.org/10.1186/1471-2148-11-235.
16. Ko JA, Kimura Y, Matsuura K, Yamamoto H, Gondo T, Inui M. 2006. PDZRN3 (LNX3, SEMCAP3) is required for the differentiation of C2C12 myoblasts into myotubes. J Cell Sci 119(Pt 24):5106-5113. http://dx.doi.org/10.1242/jcs.03290.
17. Honda T, Yamamoto H, Ishii A, Inui M. 2010. PDZRN3 negatively regulates BMP-2-induced osteoblast differentiation through inhibition of Wnt signaling. Mol Biol Cell 21:3269-3277. http://dx.doi.org/10.1091/mbc.E10-02-0117.
18. Honda T, Ishii A, Inui M. 2013. Regulation of adipocyte differentiation of 3T3-L1 cells by PDZRN3. Am J Physiol Cell Physiol 304:C1091-C1097. http://dx.doi.org/10.1152/ajpcell.00343.2012.
19. Lu Z, Je HS, Young P, Gross J, Lu B, Feng G. 2007. Regulation of synaptic growth and maturation by a synapse-associated E3 ubiquitin ligase at the neuromuscular junction. J Cell Biol 177:1077-1089. http://dx.doi.org/10.1083/jcb.200610060.
20. Wigler M, Sweet R, Sim GK, Wold B, Pellicer A, Lacy E, Maniatis T, Silverstein S, Axel R. 1979. Transformation of mammalian cells with genes from procaryotes and eucaryotes. Cell 16:777-785, http://dx.doi.org/10.1016/0092-8674(79)90093-X.
21. Butz A, Ristriani T, Hengstermann A, Denk C, Scheffner M, Hoppe-Seyler F. 2003. siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 22:5938-5945. http://dx.doi.org/10.1038/sj.onc.1206894.
22. Hong S, Laimins LA. 2013. The JAK-STAT transcriptional regulator, STAT-5, activates the ATM DNA damage pathway to induce HPV 31 genome amplification upon epithelial differentiation. PLoS Pathog 9:e1003295. http://dx.doi.org/10.1371/journal.ppat.1003295.
23. Meinke A, Barahmand-Pour F, Wöhrl S, Stoiber D, Decker T. 1996. Activation of different Stat5 isoforms contributes to cell-type-restricted signaling in response to interferons. Mol Cell Biol 16:6937-6944.
24. Tomaić V, Gardiol D, Massimi P, Ozbun M, Myers M, Banks L. 2009. Human and primate tumour viruses use PDZ binding as an evolutionarily conserved mechanism of targeting cell polarity regulators. Oncogene 28: 1-8. http://dx.doi.org/10.1038/onc.2008.365.
25. Thomas M, Massimi P, Navarro C, Borg JP, Banks L. 2005. The hScrib/Dlg apico-basal control complex is differentially targeted by HPV-16 and HPV-18 E6 proteins. Oncogene 24:6222-6230. http://dx.doi.org/10.1038/sj.onc.1208757.
26. Boon SS, Banks L. 2013. High-risk human papillomavirus E6 oncoproteins interact with 14-3-3ζ in a PDZ binding motif-dependent manner. J Virol 87:1586-1595. http://dx.doi.org/10.1128/JVI.02074-12.